149
Views
1
CrossRef citations to date
0
Altmetric
Case Reports

Candidal thrombophlebitis of central veins: case report and review

, , , , &
Pages 299-304 | Received 24 Jan 2011, Accepted 11 May 2011, Published online: 12 Sep 2011
 

Abstract

Although candidemia and central catheter septic thrombosis is quite common, central veins thrombophlebitis caused by Candida spp. is a rarely reported complication in critically ill patients. Here we report a case of thrombophlebitis of the right internal jugular and subclavian veins due to Candida albicans which occurred in a patient admitted in the intensive care unit for major trauma. The individual was eventually cured after prolonged course of antifungal therapy. We also review 24 additional cases of Candida induced central veins thrombophlebitis reported since 1978. A central vein catheter was in place in all 25 patients with 21 (84%) being admitted in an intensive care unit, 22 (88%) were receiving total parenteral nutrition and 23 (92%) undergoing a course of antibiotic therapy. Overall mortality was 16%, including two patients who received no therapy and died. In the group of patients receiving only medical therapy, the mortality rate was 13%, while no deaths were observed among those treated with combined medical and surgical therapy. Literature data suggest that Candida caused central veins thrombophlebitis is a rare and probably underdiagnosed infectious complication of the critically ill patient. Despite the dramatic presentation with persistent candidemia, mortality is low even with a conservative medical approach with prolonged fungicidal therapy through the use of amphotericin B or echinocandins. Thus, the decision for a combined surgical debridement should be assessed for each patient.

Declaration of interest: Mario Venditti (M.V.) received grants as invited speaker from Pfizer, Novartis, Merck Sharp Dohme, Astellas, Gilead, Astra Zeneca and Sanofi Aventis, and received grants as member of advisory board of Pfizer, Novartis, Merck Sharp Dohme, Astellas, Gilead, Astra Zeneca and Sanofi Aventis; Marco Falcone (M.F.) received grants as invited speaker from Pfizer, Novartis, Merck Sharp Dohme, Astellas, and received grants as member of advisory board of Pfizer, Novartis, Merck Sharp Dohme, Astellas. The other authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

This paper was first published online on Early Online on 9 September 2011.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.